145 related articles for article (PubMed ID: 35366926)
41. Comparison of quality of life after stereotactic body radiotherapy and surgery for early-stage prostate cancer.
Katz A; Ferrer M; Suárez JF;
Radiat Oncol; 2012 Nov; 7():194. PubMed ID: 23164305
[TBL] [Abstract][Full Text] [Related]
42. Stereotactic body radiotherapy as boost for organ-confined prostate cancer.
Katz AJ; Santoro M; Ashley R; Diblasio F; Witten M
Technol Cancer Res Treat; 2010 Dec; 9(6):575-82. PubMed ID: 21070079
[TBL] [Abstract][Full Text] [Related]
43. 1.5 T MR-guided and daily adapted SBRT for prostate cancer: feasibility, preliminary clinical tolerability, quality of life and patient-reported outcomes during treatment.
Alongi F; Rigo M; Figlia V; Cuccia F; Giaj-Levra N; Nicosia L; Ricchetti F; Sicignano G; De Simone A; Naccarato S; Ruggieri R; Mazzola R
Radiat Oncol; 2020 Mar; 15(1):69. PubMed ID: 32248826
[TBL] [Abstract][Full Text] [Related]
44. Patient and Dosimetric Predictors of Genitourinary and Bowel Quality of Life After Prostate SBRT: Secondary Analysis of a Multi-institutional Trial.
Wang K; Chen RC; Kane BL; Medbery CA; Underhill KJ; Gray JR; Peddada AV; Fuller DB
Int J Radiat Oncol Biol Phys; 2018 Dec; 102(5):1430-1437. PubMed ID: 30056080
[TBL] [Abstract][Full Text] [Related]
45. Stereotactic Body Radiation Therapy for Prostate Cancer: What is the Appropriate Patient-Reported Outcome for Clinical Trial Design?
Woo JA; Chen LN; Wang H; Cyr RA; Bhattasali O; Kim JS; Moures R; Yung TM; Lei S; Collins BT; Suy S; Dritschilo A; Lynch JH; Collins SP
Front Oncol; 2015; 5():77. PubMed ID: 25874188
[TBL] [Abstract][Full Text] [Related]
46. Stereotactic body radiotherapy with a focal boost to the MRI-visible tumor as monotherapy for low- and intermediate-risk prostate cancer: early results.
Aluwini S; van Rooij P; Hoogeman M; Kirkels W; Kolkman-Deurloo IK; Bangma C
Radiat Oncol; 2013 Apr; 8():84. PubMed ID: 23570391
[TBL] [Abstract][Full Text] [Related]
47. A multi-institutional phase 2 trial of prostate stereotactic body radiation therapy (SBRT) using continuous real-time evaluation of prostate motion with patient-reported quality of life.
Jackson WC; Dess RT; Litzenberg DW; Li P; Schipper M; Rosenthal SA; Chang GC; Horwitz EM; Price RA; Michalski JM; Gay HA; Wei JT; Feng M; Feng FY; Sandler HM; Wallace RE; Spratt DE; Hamstra DA
Pract Radiat Oncol; 2018; 8(1):40-47. PubMed ID: 29304991
[TBL] [Abstract][Full Text] [Related]
48. High-dose-rate stereotactic body radiation therapy for postradiation therapy locally recurrent prostatic carcinoma: Preliminary prostate-specific antigen response, disease-free survival, and toxicity assessment.
Fuller DB; Wurzer J; Shirazi R; Bridge SS; Law J; Mardirossian G
Pract Radiat Oncol; 2015; 5(6):e615-23. PubMed ID: 26059509
[TBL] [Abstract][Full Text] [Related]
49. Patient-reported urinary incontinence following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer.
Chen LN; Suy S; Wang H; Bhagat A; Woo JA; Moures RA; Kim JS; Yung TM; Lei S; Collins BT; Kowalczyk K; Dritschilo A; Lynch JH; Collins SP
Radiat Oncol; 2014 Jun; 9():148. PubMed ID: 24966110
[TBL] [Abstract][Full Text] [Related]
50. Prospective Randomized Phase II Study of Stereotactic Body Radiotherapy (SBRT) vs. Conventional Fractionated Radiotherapy (CFRT) for Chinese Patients with Early-Stage Localized Prostate Cancer.
Poon DMC; Lam D; Wong KCW; Chu CM; Cheung M; Mo F; Suen J; Ng CF; Chan ATC
Curr Oncol; 2021 Dec; 29(1):27-37. PubMed ID: 35049677
[TBL] [Abstract][Full Text] [Related]
51. Health-related quality of life after stereotactic body radiation therapy for localized prostate cancer: results from a multi-institutional consortium of prospective trials.
King CR; Collins S; Fuller D; Wang PC; Kupelian P; Steinberg M; Katz A
Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):939-45. PubMed ID: 24119836
[TBL] [Abstract][Full Text] [Related]
52. Heterogenous Dose-escalated Prostate Stereotactic Body Radiation Therapy for All Risk Prostate Cancer: Quality of Life and Clinical Outcomes of an Institutional Pilot Study.
Parsai S; Juloori A; Sedor G; Reddy CA; Thousand R; Magnelli A; Berglund RK; Stovsky M; Klein EA; Tendulkar RD; Stephans KL
Am J Clin Oncol; 2020 Jul; 43(7):469-476. PubMed ID: 32349020
[TBL] [Abstract][Full Text] [Related]
53. A single-center study of 100 consecutive patients with localized prostate cancer treated with stereotactic body radiotherapy.
Bolzicco G; Favretto MS; Satariano N; Scremin E; Tambone C; Tasca A
BMC Urol; 2013 Oct; 13():49. PubMed ID: 24134138
[TBL] [Abstract][Full Text] [Related]
54. Stereotactic body radiotherapy for oligometastatic castration sensitive prostate cancer using 1.5 T MRI-Linac: preliminary data on feasibility and acute patient-reported outcomes.
Mazzola R; Cuccia F; Figlia V; Rigo M; Nicosia L; Giaj-Levra N; Ricchetti F; Vitale C; Mantoan B; Di Paola G; De Simone A; Gurrera D; Sicignano G; Naccarato S; Ruggieri R; Alongi F
Radiol Med; 2021 Jul; 126(7):989-997. PubMed ID: 33835309
[TBL] [Abstract][Full Text] [Related]
55. A phase II trial of stereotactic body radiotherapy in 4 fractions for patients with localized prostate cancer.
Kawakami S; Tsumura H; Satoh T; Tabata K; Sekiguchi A; Kainuma T; Nakano M; Iwamura M; Ishiyama H
Radiat Oncol; 2022 Apr; 17(1):67. PubMed ID: 35379264
[TBL] [Abstract][Full Text] [Related]
56. Computed tomography versus magnetic resonance imaging in high-dose-rate prostate brachytherapy planning: The impact on patient-reported health-related quality of life.
Harris AA; Wu M; Deirmenjian JM; Shea SM; Kang H; Patel R; Fielder D; Mysz ML; Harkenrider MM; Solanki AA
Brachytherapy; 2021; 20(1):66-74. PubMed ID: 33160849
[TBL] [Abstract][Full Text] [Related]
57. Early Exploratory Analysis for Patient-reported Quality of Life and Dosimetric Correlates in Hypofractionated Stereotactic Body Radiation Therapy (SBRT) for Low-risk and Intermediate-risk Prostate Cancer: Interim Results from a Prospective Phase II Clinical Trial.
Iarrobino NA; Gill B; Sutera PA; Kalash R; D' Ambrosio D; Heron DE
Am J Clin Oncol; 2019 Nov; 42(11):856-861. PubMed ID: 31584457
[TBL] [Abstract][Full Text] [Related]
58. A pilot study of intensity modulated radiation therapy with hypofractionated stereotactic body radiation therapy (SBRT) boost in the treatment of intermediate- to high-risk prostate cancer.
Oermann EK; Slack RS; Hanscom HN; Lei S; Suy S; Park HU; Kim JS; Sherer BA; Collins BT; Satinsky AN; Harter KW; Batipps GP; Constantinople NL; Dejter SW; Maxted WC; Regan JB; Pahira JJ; McGeagh KG; Jha RC; Dawson NA; Dritschilo A; Lynch JH; Collins SP
Technol Cancer Res Treat; 2010 Oct; 9(5):453-62. PubMed ID: 20815416
[TBL] [Abstract][Full Text] [Related]
59. Patient-reported Outcomes and Late Toxicity After Postprostatectomy Intensity-modulated Radiation Therapy.
Akthar AS; Liao C; Eggener SE; Liauw SL
Eur Urol; 2019 Nov; 76(5):686-692. PubMed ID: 31113644
[TBL] [Abstract][Full Text] [Related]
60. Multi-Institutional Analysis of Prostate-Specific Antigen Kinetics After Stereotactic Body Radiation Therapy.
Jiang NY; Dang AT; Yuan Y; Chu FI; Shabsovich D; King CR; Collins SP; Aghdam N; Suy S; Mantz CA; Miszczyk L; Napieralska A; Namysl-Kaletka A; Bagshaw H; Prionas N; Buyyounouski MK; Jackson WC; Spratt DE; Nickols NG; Steinberg ML; Kupelian PA; Kishan AU
Int J Radiat Oncol Biol Phys; 2019 Nov; 105(3):628-636. PubMed ID: 31276777
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
